- $7.90bn
- $9.12bn
- $3.78bn
Russia puts Aptar Europe Holding under temporary administration
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Aptargroup Inc reports results for the quarter ended June 30 - Earnings Summary
Aptar Q2 sales beat estimates on strength in consumer healthcare and injectables
Brief: Aptar Q2 Adjusted EPS USD 1.42 Vs. IBES Estimate USD 1.35
U.S. RESEARCH ROUNDUP-Chipotle Mexican Grill, Honeywell, Tesla
Aptar Q1 sales rise 11%, beat estimates; EPS falls as prescription sales decline
Brief: Aptar Digital Health Partners With Enable Injections For Enfuse® Companion Digital Solution
Aptar beats Q4 revenue, profit estimates; announces $600 mln buyback
Brief: Aptargroup Inc Files For Senior Notes Offering, Size Not Disclosed - SEC Filing
U.S. RESEARCH ROUNDUP- Crowdstrike, Guardant Health, Palantir Technologies
AptarGroup beats Q3 sales expectations
Epinephrine nasal spray maker ARS sues Aptar alleging device supply monopoly
Brief: Aptar Increases Quarterly Dividend By Nearly 7% Signaling Continued Momentum And Long-Term Strength
U.S. RESEARCH ROUNDUP-Alphabet, Copart, Leidos
U.S. RESEARCH ROUNDUP-Alphabet, Copart, Leidos
Aptargroup Inc reports results for the quarter ended June 30 - Earnings Summary
Aptar Q2 sales rise 6% to $966 mln, beat estimates
Aptargroup Inc reports results for the quarter ended March 31 - Earnings Summary